News

FDA approves Roche’s Susvimo for diabetic retinopathy
Susvimo can help people with diabetic retinopathy (DR) maintain their vision and prevent progression to blindness with only one treatment every nine monthsSusvimo’s innovative technology via the Port ...
Applied Clinical Trials Online13d
Roche’s Susvimo Lands FDA Approval for Diabetic Retinopathy Based on Phase III Pavilion Trial Data
One-year results from the Pavilion study showed patients who received Susvimo (ranibizumab) refilled every nine months ...
Roche Gets FDA Nod for Label Expansion of Susvimo for Third Indication
FDA approves RHHBY's Susvimo for diabetic retinopathy, its third indication, offering 9-month relief with one treatment.
Medical Dialogues13d
Roche Susvimo gets USFDA green light for Diabetic Retinopathy
Basel: Roche has received approval from the US Food and Drug Administration (FDA) for Susvimo (ranibizumab injection) 100 ...
Mena FN14d
FDA Approves Roche’S Susvimo For Diabetic Retinopathy
22 May 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of ...
The Pharma Letter13d
FDA nod for Roche’s Susvimo for diabetic retinopathy
All the news that moves the needle in pharma and biotech Exclusive features, podcasts, interviews, data analyses and ...
Finanznachrichten13d
F. Hoffmann-La Roche Ltd: FDA approves Roche's Susvimo for diabetic retinopathy
22 May 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of ...
Le Lézard14d
FDA Approves Genentech's Susvimo for Diabetic Retinopathy
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the ...